Korro Bio received U.S. FDA's orphan drug designation for investigational medicine KRRO-110 to treat Alpha-1 Antitrypsin ...

Korro Bio (KRRO) announced that the U.S. Food and Drug Administration has granted orphan drug designation, ODD, to the investigational medicine ...

Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading. The stock is ...

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...

Over the 50 years since UnitedHealth was founded, Richard T. Burke (81) has given few interviews. Now he has given an ...

Korro Bio recently began a Phase 1/2 test of KRRO-110, an RNA-editing therapy for AATD. Last summer, biotech startup AIRNA raised $60 million to advance to the clinic in 2025 with its experimental ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...

After hours: March 12 at 6:08:13 PM EDT Loading Chart for KRRO ...

Explore Korro Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for KRRO. U.S. stocks reacted positively following the Federal Open Market Committee's ...

After hours: March 12 at 4:05:05 PM EDT Loading Chart for CAMP ...